Latest News

Ocugen announces positive preliminary data from OCU410 Phase 1 clinical trial for geographic atrophy
Ocugen announces positive preliminary data from OCU410 Phase 1 clinical trial for geographic atrophy

November 20th 2024

Key findings include reduced lesion growth, retinal tissue preservation, and improved visual function, demonstrating significant potential for the treatment option.

Excellence across the board at the 2024 Euretina Congress
Excellence across the board at the 2024 Euretina Congress

November 20th 2024

Alkeus Pharmaceuticals receives FDA Rare Pediatric Disease and Fast Track designations for gildeuretinol as treatment for Stargardt disease
Alkeus Pharmaceuticals receives FDA Rare Pediatric Disease and Fast Track designations for gildeuretinol as treatment for Stargardt disease

November 19th 2024

The CHMP issues positive opinion for the marketing authorization of FYB203
The CHMP issues positive opinion for the marketing authorization of FYB203

November 19th 2024

A sign for the US FDA outside its headquarters. ©Tada Images – stock.adobe.com
US FDA issues Complete Response Letter for avacincaptad pegol intravitreal solution (IZERVAY)

November 19th 2024

Latest Videos

Latest News

© 2024 MJH Life Sciences

All rights reserved.